Moderna's Massive Run Cools Off While the MACD Flashes a Warning
Moderna is still crushing the S&P 500 over three months, but a bearish MACD cross and thin volume suggest the easy gains are behind it for now.
Relative Strength: No Contest, But the Gap Is Narrowing
Measured against the broad market, Moderna isn't in the same conversation as the S&P 500 lately, it's in a different league entirely. Over three months, MRNA is up 272.25% while the S&P 500 (SPY) has gained a respectable but pedestrian 3.99%. Even over the past month the stock is ahead, up 5.97% versus the index's 0.92%.
But zoom into the last five sessions and the story flips. Moderna has dropped 12.29% over that stretch while the S&P 500 is basically flat, down just 0.24%. That's a sharp reversal in short-term relative strength, and it's worth paying attention to even though the longer-term trend still favors the stock by a wide margin.
Trend and Moving Averages
As of the close on October 28, 2026, Moderna sits at $215.61, up 3.67% on the day. The stock remains in a technical uptrend: price is above a rising 50-day moving average ($179.78), and the 50-day is above the 200-day ($84.77). That's about as textbook bullish as a long-term structure gets, and the stock is 19.93% above its 50-day and a staggering 154.36% above its 200-day.
That said, the 200-day distance is a reminder of just how far this move has already traveled. Price is sitting just above its 20-day average of $211.94, which is the first line of support the bulls need to hold.
Momentum: RSI Neutral, MACD Rolling Over
RSI14 reads 55.5, which is neutral territory, neither overbought nor oversold. That's actually a notable cooling off given the size of the three-month advance.
The MACD is the bigger flag here. MACD sits at 10.84, below its signal line at 15.31, producing a negative histogram reading of -4.47. The fact sheet confirms a bearish MACD crossover within the last five sessions. That lines up with the five-day pullback and suggests momentum is fading even as the broader trend stays intact.
Volume Tells a Quiet Story
Volume came in at 8,264,564 shares, only 0.42 times the 20-day average. That's thin participation on a day where the stock bounced 3.67%. A bounce on light volume carries less conviction than one backed by heavy trading, so this rally attempt should be watched for confirmation rather than taken as a sign sellers have been overrun.
Levels That Matter
Support sits at $182.50, with a deeper floor at $133.33. On the upside, the 52-week high at $254.48 is the key resistance, with the stock currently 15.27% below that mark after the recent pullback from levels near $245.81 just a few sessions ago.
A close that reclaims the 20-day average near $211.94 and pushes back above the recent swing highs would support the idea that the pullback was just a shakeout within the larger uptrend. A break below the $182.50 support level, on the other hand, would call the near-term structure into question and open the door toward the $133.33 zone. With ATR14 at $24.82 (11.51% of price), this stock continues to move in wide, fast swings, so position sizing should account for that volatility either way.

